Company intelligence / Profile preview
Botanix Pharmaceuticals
Perth, Western Australia, Australiabotanixpharma.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Sofdra™ (sofpironium bromide gel) was recently approved by the US FDA for primary axillary hyperhidrosis after demonstrating statistical significance on all endpoints with a favorable safety profile in Phase III trials. Other pipeline assets have shown positive results in Phase I/II studies, particularly BTX1702 for rosacea and BTX1801 for antimicrobial use.[1][6][10]
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small molecules (notably synthetic cannabinoids and sofpironium bromide)[7][10]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships publicly disclosed as of May 2025; exclusive license to Permetrex® technology.[7]
Beyond the preview
Go deeper on Botanix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Botanix Pharmaceuticals.